China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its Category 1 drug candidate STC007. The study will focus on moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adults receiving hemodialysis (HD).
Drug Profile
STC007 is a candidate molecule developed through the combination of computer-aided drug molecular design (CADD) and structure-activity relationship (SAR). The drug binds to the KOR receptor, an inhibitory G protein-coupled receptor (GPCR) involved in pain, itching, neuroendocrine, emotional behavior, cognition, and other important physiological activities. STC007 has demonstrated a good analgesic effect in three rodent pain models. Toxicology studies have shown no obvious adverse reactions, indicating a favorable druggability and safety profile with no significant risk of addiction.
Future Implications
The NMPA’s approval to proceed with the clinical study of STC007 marks a significant step forward in the development of treatments for CKD-aP. Sun-Novo’s innovative approach to drug design and its focus on addressing unmet medical needs highlight the company’s commitment to advancing therapeutic options for patients with chronic conditions.-Fineline Info & Tech
